CL2017001563A1 - Formulación de virus de herpes simple estable congelada - Google Patents

Formulación de virus de herpes simple estable congelada

Info

Publication number
CL2017001563A1
CL2017001563A1 CL2017001563A CL2017001563A CL2017001563A1 CL 2017001563 A1 CL2017001563 A1 CL 2017001563A1 CL 2017001563 A CL2017001563 A CL 2017001563A CL 2017001563 A CL2017001563 A CL 2017001563A CL 2017001563 A1 CL2017001563 A1 CL 2017001563A1
Authority
CL
Chile
Prior art keywords
herpes simplex
simplex virus
virus formulation
frozen
stable
Prior art date
Application number
CL2017001563A
Other languages
English (en)
Inventor
Jennifer R Litowski
Christine Claudia Siska
Bruce Arthur Kerwin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2017001563A1 publication Critical patent/CL2017001563A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>SE DESCRIBE UNA COMPOSICIÓN DE VIRUS VIVO QUE SE MANTIENE NO INFECTIVA Y PROPORCIONA ESTABILIDAD MEJORADA DEL VIRUS DURANTE UNO O MÁS CICLOS DE CONGELADO/DESCONGELADO Y/O DURANTE EL ALMACENADO A LARGO PLAZO EN UN ESTADO LÍQUIDO A TEMPERATURAS EN EL INTERVALO DESDE APENAS ARRIBA DE LA CONGELACIÓN HASTA TEMPERATURAS AMBIENTE.</p>
CL2017001563A 2014-12-18 2017-06-15 Formulación de virus de herpes simple estable congelada CL2017001563A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462093663P 2014-12-18 2014-12-18

Publications (1)

Publication Number Publication Date
CL2017001563A1 true CL2017001563A1 (es) 2018-01-26

Family

ID=55229814

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001563A CL2017001563A1 (es) 2014-12-18 2017-06-15 Formulación de virus de herpes simple estable congelada

Country Status (18)

Country Link
US (2) US20170360857A1 (es)
EP (1) EP3234114B9 (es)
JP (2) JP6975041B2 (es)
KR (2) KR20230107375A (es)
CN (1) CN107580626A (es)
AU (3) AU2015362687B2 (es)
BR (1) BR112017013009A2 (es)
CA (1) CA2971201A1 (es)
CL (1) CL2017001563A1 (es)
CO (1) CO2017007086A2 (es)
EA (1) EA201791382A1 (es)
ES (1) ES2948037T3 (es)
IL (3) IL308119B2 (es)
MA (1) MA40948A (es)
MX (2) MX2017008013A (es)
SG (1) SG11201704975SA (es)
WO (1) WO2016100364A1 (es)
ZA (1) ZA201704695B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017013421A1 (en) * 2015-07-20 2017-01-26 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
MX2019012741A (es) 2017-04-28 2020-01-21 Merck Sharp & Dohme Biomarcadores para agentes terapeuticos contra el cancer.
WO2019213509A1 (en) * 2018-05-03 2019-11-07 Rutgers, The State University Of New Jersey Compositions and methods for treating cancer
CN109161562A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭肝癌细胞的新型溶瘤病毒及其构建方法
MX2021007639A (es) * 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
WO2022006745A1 (en) * 2020-07-07 2022-01-13 Oriengene Biotechnology Ltd Guide rna for hsv-1 gene editing and method thereof
EP4282955A4 (en) * 2021-01-19 2025-01-15 Nitta Gelatin Inc. VIRUS STABILIZER, GELATIN HYDROLYSATE FOR VIRUS STABILIZER, AND COMPOSITION CONTAINING VIRUS
CN116421734A (zh) * 2021-12-30 2023-07-14 深圳复诺健生物科技有限公司 适用于溶瘤病毒的冻干保护剂及其应用
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1141338A4 (en) 1998-12-31 2002-09-25 Arch Dev Corp RECOMBINANT HERPES SIMPLEX VIRUS FOR TREATING NEOPLASTIC DISEASES
AU2905199A (en) 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
ES2366608T3 (es) 2001-03-27 2011-10-21 The General Hospital Corporation Vectores víricos y su uso en métodos terapéuticos.
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
JP2005521398A (ja) * 2002-03-27 2005-07-21 ベイラー　カレッジ　オブ　メディスン 癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
SI2144998T1 (sl) * 2007-04-06 2017-05-31 Takeda Vaccines, Inc. Postopki in sestavki za žive atenuirane viruse
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
US20110243988A1 (en) * 2009-10-01 2011-10-06 Aridis Pharmaceuticals Methods and Compositions for Stabilization of a Virus Vaccine
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN101926990A (zh) * 2010-09-21 2010-12-29 中山大学 肿大细胞病毒vsocs基因缺失减毒活疫苗及其制备方法和应用
WO2013006795A2 (en) 2011-07-07 2013-01-10 Humanitas International Foundation Antiviral compositions and methods of their use
ES2765880T3 (es) * 2012-01-09 2020-06-11 Sanofi Pasteur Biologics Llc Purificación del virus del herpes
EP2852662B1 (en) * 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesvirus compositions and related methods
FI3381942T4 (fi) * 2012-08-30 2025-12-16 Amgen Inc Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen

Also Published As

Publication number Publication date
MX2023012564A (es) 2023-11-08
SG11201704975SA (en) 2017-07-28
AU2022201523B2 (en) 2024-12-12
IL252942A0 (en) 2017-08-31
ES2948037T3 (es) 2023-08-30
BR112017013009A2 (pt) 2018-06-26
KR20230107375A (ko) 2023-07-14
CN107580626A (zh) 2018-01-12
US20170360857A1 (en) 2017-12-21
EA201791382A1 (ru) 2017-10-31
MX2017008013A (es) 2018-03-06
IL308119B1 (en) 2025-07-01
KR102549746B1 (ko) 2023-07-03
IL300202B2 (en) 2024-04-01
EP3234114B9 (en) 2023-06-14
AU2022201523A1 (en) 2022-03-24
AU2015362687B2 (en) 2021-12-09
IL308119B2 (en) 2025-11-01
EP3234114A1 (en) 2017-10-25
AU2015362687A1 (en) 2017-07-06
US20210052680A1 (en) 2021-02-25
AU2025201675A1 (en) 2025-03-27
IL308119A (en) 2023-12-01
AU2022201523C1 (en) 2025-10-02
IL300202B1 (en) 2023-12-01
JP2021072795A (ja) 2021-05-13
JP2018502078A (ja) 2018-01-25
EP3234114B1 (en) 2023-04-12
IL300202A (en) 2023-03-01
MA40948A (fr) 2017-10-25
ZA201704695B (en) 2023-12-20
CA2971201A1 (en) 2016-06-23
KR20170095270A (ko) 2017-08-22
HK1245823A1 (en) 2018-08-31
JP6975041B2 (ja) 2021-12-01
WO2016100364A1 (en) 2016-06-23
CO2017007086A2 (es) 2017-10-10

Similar Documents

Publication Publication Date Title
CO2017007086A2 (es) Formulación congelada estable de virus de herpes simple
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
CO2019001448A2 (es) Composiciones y métodos para estabilizar flavivirus con formulaciones mejoradas
CU20180154A7 (es) Formulación farmacéutica líquida estable
CL2016003125A1 (es) Dispositivo de conexión de los elementos estructurales de nervaduras y estructuras reticulares
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
AR094348A1 (es) Diferenciación de células madre embrionarias humanas a células pancreáticas endocrinas con el uso de reguladores hb9
PL3232777T3 (pl) Przechowywanie i transport próbki biologicznej ex vivo obejmujące zastosowanie ultradźwięków
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
EA201692236A1 (ru) Небулайзер и контейнер
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MX384877B (es) Composiciones de éster de colina de ácido lipoico y métodos de uso.
EP3372921A4 (en) EVAPORATOR AND REFRIGERATOR WITH IT
MX2016017025A (es) Formulaciones de proteinas.
IL249376B (en) Proliferation and transplantation of stem cells using notch1 and/or notch2 agonists
MX377168B (es) Sistemas generadores de impulso electrico que utilizan acoplamiento capacitivo.
LT3419595T (lt) Stabili skysta gonadotropino kompozicija
AR101332A1 (es) Búsqueda de forma mediante cuantificador de vectores pirámide
CL2017001834A1 (es) Contenedor de palé que tiene un forro interior
IL252613A0 (en) Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells
EA201692239A1 (ru) Небулайзер
CL2016001801A1 (es) Proceso para la reconstitución de una forma sólida de una composición farmacéutica.
TWD168034S (zh) 凍結保存容器
Iagar et al. Asymptotic behavior for a singular diffusion equation with gradient absorption
MX2020001942A (es) Composiciones de perfusion y metodos de uso de alfa-1-anti-tripsina en perfusion de organos ex vivo.